After mixed results in previous randomised trials, the IL-6 inhibitor tocilizumab has shown positive effects in treating critically ill patients with COVID-19 in a study from Europe. The preliminary findings, which are yet to be published, come from 303 patients with severe COVID-19 pneumonia enrolled in the REMAP-CAP trial, led by Imperial College London and ...
At last – some positive results for tocilizumab in COVID-19
By Michael Woodhead
23 Nov 2020